We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLAidentical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMGpositive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day þ 360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.
Introduction
Allogeneic hematopoietic stem cell transplantation may be considered a treatment of choice for high-risk hematological malignancies. Recently, it has been appreciated that allografting can be considered a form of adoptive immunotherapy also in metastatic, chemotherapy-resistant selected solid tumors. A graft-versus-tumor (GVT) effect, analogous to the graft-versus-leukemia effect, has been observed to occur after allografting in patients with advanced renal cell cancer. 1, 2 Clinical responses have been reported in patients with advanced breast cancer after myeloablative allografting 3, 4 and, more recently, after reduced-intensity conditioning and peripheral blood allografting. 2, 5, 6 This suggests that T-cellmediated responses against yet to be determined minor histocompatibility alloantigens can mediate clinically manifest GVT activity. 7 The place of allografting in the treatment of advanced breast cancer is still under investigation. As already observed in other solid tumors, 8 adoptive cellular immunotherapy may be able to control minimal disease, but not to induce remission of clinically evident bulky disease. Thus, a methodology for assessing response of minimal disease to allografting is needed.
Breast cancer has long been considered a systemic disease and, indeed, isolated tumor cells may be found with sensitive techniques in the peripheral blood 9 and bone marrow (BM) [10] [11] [12] [13] [14] [15] [16] of patients with early and advanced disease. The presence of isolated tumor cells in the BM of patients with stage II-III operated breast cancer, assessed by immunocytochemistry, strongly correlated with disease-free survival and overall survival in a large prospective study 17 and in a recent pooled analysis of 4703 patients. 18 Cristofanilli et al.
19
recently reported that isolated tumor cells in the BM are an independent prognostic factor for survival also in advanced disease. It is not known whether isolated tumor cells should be considered simply a marker of disease burden or they are clonogenic cells capable of causing relapse. Notably, these cells are in a quiescent phase of the cell cycle, 20 and they are relatively resistant to adjuvant systemic chemotherapy. 21 Given the relative lack of efficacy of systemic chemotherapy, it has been hypothesized that they may be targets of active or adoptive immunotherapy approaches. 22 Allografting may be considered the most potent modality of adoptive immunotherapy clinically available.
The immunocytochemical method, which utilizes monoclonal antibodies reactive with cytokeratin molecules, has been utilized by most investigators for assessing the contamination of BM cells by breast cancer cells. 23 Immunocytochemistry is relatively easy to apply, not requiring sophisticated devices, and standardization criteria have been reported. 24 We have recently found that a nested RT-PCR assay for the expression of maspin and mammaglobin (MMG) genes is a sensitive and specific assay for detection of breast cancer cells in the BM. 25 In comparison with immunocytochemical assay, RT-PCR has the advantage of being operator-independent, and allows a permanent record of the results. Moreover, a quantitative approach with real-time PCR may be attempted to quantify the burden of the disease. 26, 27 Thus, RT-PCR MMG assessment may give information on the effect of allografting on breast cancer cells in the BM.
We have assessed MMG expression by RT-PCR in consecutive BM aspirates in eight patients with advanced breast cancer after reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-breast cancer effect on micrometastatic disease.
Materials and methods

Patient characteristics
The study was approved by the IRB of San Raffaele Scientific Institute, and written informed consent was obtained from the patient and the donor. Eligible patients were less than 60-year-old women with metastatic breast cancer refractory to standard treatments, evaluable disease, a life expectancy of at least 6 months, and with an HLAidentical sibling donor. Three patients had a BM involvement by breast cancer cells before allografting, as documented by BM biopsy. The main characteristics of the patients are reported in Table 1 .
Allografting program
The preparative regimen has been described previously. 2 Briefly, it consisted of 10 mg/kg thiotepa on day À6 and 30 mg/kg cyclophosphamide followed by 30 mg/m 2 fludarabine on days À4 and À3. One patient received 5 mg/kg thiotepa because of close proximity to autografting. Patients received lenograstim-mobilized peripheral blood progenitors from their sibling donors on day 0 (median dose 7.7 Â 10 6 CD34 þ cells/kg of body weight of the recipient, range 4.5-11.6). Cyclosporine A, 1-2 mg/kg/day, and short-course methotrexate (10 mg/m 2 on day 1 and 8 mg/m 2 on days 3 and 6) were utilized as acute GVHD prophylaxis. Cyclosporine was administered at full dose through day þ 70 and then tapered by 20% each week, or earlier in the case of disease progression. Patients who had stable or progressive disease after cyclosporine withdrawal and no evidence of acute GVHD received donor lymphocyte infusions (DLIs) at escalating doses (10 7 , 5 Â 10 7 , and 10 8 CD3 þ cells/kg body weight of the recipient) at monthly intervals. Donor-recipient chimerism analysis was carried out on BM cells and on peripheral blood mononuclear cells using PCR of informative minisatellite regions at monthly intervals after allografting. All patients were evaluated by BM biopsy, total-body computed tomography scan, and other specific exams, depending on the site of disease, before allografting and at monthly intervals.
RT-PCR analysis of MMG Analysis of MMG expression was carried out on leftover BM cells utilized for chimerism analysis. The nested RT-PCR assay for detection of MMG expression has been already described. 25 
Results
Engraftment, chimerism, DLI, and response All patients had a prompt engraftment of allogeneic cells. At day þ 60 after transplant, a peripheral blood and BM full donor chimerism was documented in all nine patients. Cyclosporine A was withdrawn at median day þ 73 (range, 44-145). DLIs were made in patients 1-7, for persistent or progressive disease, at median day þ 130 (range, 90-255). DLI doses ranged from 1 Â 10 7 to 10 Â 10 7 CD3 þ cells/kg body weight. Patient 7 received two infusions of 2 Â 10 7 and 10 Â 10 7 CD3 þ cells, respectively. An objective response to DLI was achieved in one case (partial remission; patient no. 7 after the second infusion), it was not evaluable in two patients (nos. 3 and 6), and no response was observed in four patients (nos. 1, 2, 5, and 7 at the first infusion) ( Table 2 ).
Baseline assessment of MMG expression in the BM Before receiving the preparative regimen, in seven out of eight patients it was possible to determine MMG expression in the BM. In patient 3, BM sample volume was not sufficient for RT-PCR determination. Three patients were in partial remission, one had stable disease, and five had progressive disease before the preparative regimen. There was no correlation between disease status at transplant and MMG expression in the BM prior to transplant. Patients with BM metastases were all positive for MMG. Patient 2 had a negative BM biopsy and a positive MMG RT-PCR (Table 1) . 
MMG expression in the BM after conditioning regimen
At day þ 30 after allografting, in only one case (patient 7), BM became negative for MMG expression. This patient did not have a systemic disease response concurrently with MMG negativity after chemotherapy. This result may be due to the effect of systemic chemotherapy given before allogeneic cell transplant as the preparative regimen. However, this tumor response was of short duration, and the BM was found to be MMG positive on the subsequent test at day þ 60.
MMG expression in the BM and tumor response after allografting
In patients 4 and 7, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression in the BM, at days þ 200 and þ 180, respectively. In these two patients, an immune manipulation (cyclosporine A withdrawal and DLI) preceded the response. A temporal correlation between systemic responses and BM MMG responses was observed in these patients. Patient 7 has already been described in a previous report. 2 In this patient, an objective disease response at the pleural site of disease occurred at day þ 180 after allografting and at day þ 50 after DLI. This response was concurrent with a grade II acute GVHD and was associated with a negativization of MMG expression. In this patient, a disease progression at day þ 360 was observed, and MMG in the BM returned positive (Figure 1) . In addition, patients 1 and 2, who received the allografting while in progressive disease, enjoyed a period of stable disease from day þ 360 on, in association with a negativization of MMG expression. In patients 4 and 8, progression of the disease was accompanied by MMG RT-PCR turning from negative to positive at days þ 360 and þ 120, respectively.
Discussion
The relevance of minimal residual disease (MRD) in the BM of patients with early and advanced breast cancer has already been highlighted. The presence of isolated tumor cells in the BM correlates to disease-free survival and overall survival in early breast cancer. 17 In advanced disease, it is an unfavorable prognostic factor. [10] [11] [12] 15, 16 In the setting of high-dose chemotherapy and autologous stem cell transplant, isolated tumor cells have been found in the BM and in the aphereses of patients undergoing progenitor cell harvest and autografting, 27 and in some reports this finding correlated with a worse event-free survival. 28, 29 Methods for determining MRD in the BM and peripheral blood of breast cancer patients include immunocytochemistry, immunohistochemistry, and RT-PCR of relevant breast cancer-associated genes. MMG is a protein associated with most breast cancers, and RT-PCR determination of MMG expression in BM has been found to be specific and sensitive. 24 Its expression may inversely correlate with tumor burden and prognosis. 30 We elected to study BM rather than peripheral blood cells for several reasons: firstly, bone and BM are usual sites of metastasis by breast cancer; secondly, most studies to date have focused on BM micrometastases, and have found a correlation among presence of tumor cells and survival; [15] [16] [17] [18] thirdly, guidelines for analysis and evaluation of isolated tumor cells in the BM have been issued by a scientific society (ISHAGE, now ISCT); 31 and finally, BM samples were already available because of chimerism analysis, without the need to perform fastidious ad hoc sampling.
Among newer treatment modalities, allogeneic BM transplant has been utilized in breast cancer. Its mechanism of action is based on the immune attack of the donor cytotoxic T lymphocytes against malignant cells. It should be noted that malignant cells residing in the BM are scarcely sensitive to adjuvant chemotherapy. Thus, an immunologic effect could be effective in removing them from BM. In our small series, we observed objective and BM responses at day þ 180, approximately 6 months after allografting. This is not surprising, as an immune effect is typically slow to ensue after transplant. Childs et al. 1 reported that the median time to response after allografting in renal cell cancer is 5 months. A further reason for the delayed occurrence of a GVT effect may be the mixed chimerism status, which is frequently observed after nonmyeloablative conditioning. In our setting, mixed chimerism may not have contributed to the delay, because all our patients were already full chimeras at day þ 60 after allografting. The clinical responses we observed in two patients were associated with reversal to a negative status of the MMG expression. In two informative cases, progression of the disease was linked to a change from negative to positive of the MMG expression. Although preliminary, these observations point to a possible GVT effect of the transplant against micrometastatic disease in the BM. This observation is reinforced by the fact that negativizations occurred several months after transplant, after withdrawal of the immune suppression, and were coupled with clinical objective responses. We also confirm that, in only one case out of four, chemotherapy was able to transiently induce in vivo negativity of BM micrometastasis, as already noted. 21 In conclusion, the data from this study suggest that assessment of MRD in the BM by RT-PCR may be a useful adjunct to clinical and radiological restaging. This is in agreement with the notion that low tumor burden, especially isolated tumor cells, may be particularly susceptible to an immunologic effect mediated by cytotoxic T lymphocytes, which may be crucial for eradication of minimal disease after allogeneic hematopoietic stem cell transplantation. Notably, Carella et al. 32 recently reported low toxicity and extended survival after reduced-intensity allografts in patients induced to an MRD status with a cytoreductive autograft.
As the molecular targets of the GVT effect in breast cancer become clear, the clinical relevance of the study of MRD in the BM may be further elucidated.
